Replies to post #27699 on Marker Therapeutics Inc (MRKR)

[guydiamond]

I did not hear any spin. Or anything blatant. All sounded like solid science and very positive. It sounded like the doctors were very excited.

On pancreatic cancer pep mix optimization, it sounded like they were edging toward doing a gen 2 product of incorporating antigens from epitope spread after the initial dose of the current mix. Sounded like, of the factors weighing on moving forward with a good product, the current mix was enough to generate a very positive response, and eliciting the epitope spreading, and they believe the larger impact would come from incorporating the larger players in the new epitopes vs starting again with a new optimized pep mix.

Also, no patients who experienced a response from multitaa declined while they were still on the therapy, if any experienced decline after a response, it was after the therapy was completed (6 doses).

Dose optimization is something they will evaluate, 6 doses was the protocol, more doses / cell count optimization is possible as there is no adverse reaction to the therapy.

In arm A, the CR / PR responses were not part of the chemo alone, all came in a few months after being on multitaa.

[attilathehunt]

I’m sure many of us submitted questions and weren’t addressed. We most likely asked the tougher questions. I was surprised no one ask what would it take to obtain additional approval? Everyone who spoke appeared to be very encouraged/excited about the results.

It looks like they need to complete enrollment of 15 each in each arm and then see what happens at 9 months (after 6 infusions). It appears we won’t see the completed study until next summer. I hope they provide interim updates.